Cardinal Health, Inc.

New York Stock Exchange
Back to all articles
Slightly Bullish +25

Cardinal Health (CAH) Stock Moves -1.64%: What You Should Know

Earnings report AI-generated analysis

📉 Cardinal Health shares closed down 1.64% at $222.04, extending a monthly decline of 2.85%.

📈 Analysts expect quarterly EPS of $2.92, marking a 14.51% increase from the prior-year quarter.

💰 Revenue is forecasted to reach $66.96 billion for the quarter, up 4.6% year-over-year.

📅 Full-year earnings are projected at $12.55 per share with revenue of $266.02 billion.

🏆 The company maintains a Zacks Rank #3 (Hold) with no recent changes to consensus estimates.

💵 Cardinal Health trades at a Forward P/E ratio of 17.99, slightly above the industry average of 16.97.

📊 The stock has a PEG ratio of 1.36 compared to an industry average of 1.91 for Medical - Dental Supplies stocks.

Bullish Signals
  • Analysts project quarterly EPS of $2.92, representing a significant 14.51% increase from the prior-year quarter.
  • Full-year earnings are expected to grow by 11.46% to $12.55 per share, indicating strong long-term growth expectations.
Risk Factors
  • Shares closed down 1.64% today and have lost 2.85% over the past month, trailing the broader Medical sector decline.
  • The stock trades at a Forward P/E ratio of 17.99, which represents a premium valuation compared to the industry average of 16.97.
Full Analysis
Cardinal Health (CAH) shares closed down 1.64% at $222.04, continuing a broader decline for the stock over the past month which saw a 2.85% drop. This underperformance occurred while the wider Medical sector fell 3.65%, contrasting with gains in the Nasdaq and S&P 500. Analysts are closely monitoring Cardinal Health ahead of its upcoming earnings disclosure, with consensus estimates projecting an EPS of $2.92, representing a 14.51% increase from the prior-year quarter. Revenue is expected to reach $66.96 billion, up 4.6% year-over-year. Full-year projections indicate earnings of $12.55 per share and revenue of $266.02 billion, reflecting anticipated growth rates of +11.46% and +4.63% respectively from the prior year. The company currently holds a Zacks Rank #3 (Hold) with no recent changes to consensus EPS estimates.